Bicara Therapeutics Inc. Operating Expenses
Bicara Therapeutics Inc. (BCAX) reported Operating Expenses of $59.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- Bicara Therapeutics Inc. operating expenses for the quarter ending 2026-06-30 was $59.95M, a 87.24% increase year-over-year.
- Bicara Therapeutics Inc. operating expenses for the quarter ending 2026-03-31 was $60.24M, a 44.16% increase year-over-year.
- Bicara Therapeutics Inc. operating expenses for the quarter ending 2025-12-31 was $41.12M, a 54.38% increase year-over-year.
- Bicara Therapeutics Inc. operating expenses for the quarter ending 2025-09-30 was $40.68M, a 97.19% increase year-over-year.
- Bicara Therapeutics Inc. operating expenses for fiscal 2025 was $155.60M, a 88.87% increase from fiscal 2024.
- Bicara Therapeutics Inc. operating expenses for fiscal 2024 was $82.39M, a 106.55% increase from fiscal 2023.
- Bicara Therapeutics Inc. operating expenses for fiscal 2023 was $39.89M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $59.95M 10-Q · filed 2026-08-11 | $120.19M 10-Q · filed 2026-08-11 | $161.31M derived: sum of 3 quarters · filed 2026-08-11 | $201.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $60.24M 10-Q · filed 2026-05-11 | $101.36M derived: sum of 2 quarters · filed 2026-05-11 | $142.04M derived: sum of 3 quarters · filed 2026-05-11 | $174.06M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $41.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $81.80M derived: sum of 2 quarters · filed 2026-03-30 | $113.82M derived: sum of 3 quarters · filed 2026-08-11 | $155.60M 10-K · filed 2026-03-30 |
| 2025-09-30 | $40.68M 10-Q · filed 2025-11-10 | $72.69M derived: sum of 2 quarters · filed 2026-08-11 | $114.48M 10-Q · filed 2025-11-10 | $141.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $32.02M 10-Q · filed 2026-08-11 | $73.81M 10-Q · filed 2026-08-11 | $100.44M derived: sum of 3 quarters · filed 2026-08-11 | $121.07M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $41.79M 10-Q · filed 2026-05-11 | $68.42M derived: sum of 2 quarters · filed 2026-05-11 | $89.05M derived: sum of 3 quarters · filed 2026-05-11 | $108.80M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $26.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $47.27M derived: sum of 2 quarters · filed 2026-03-30 | $67.02M derived: sum of 3 quarters · filed 2026-03-30 | $82.39M 10-K · filed 2026-03-30 |
| 2024-09-30 | $20.63M 10-Q · filed 2025-11-10 | $40.38M derived: sum of 2 quarters · filed 2025-11-10 | $55.75M 10-Q · filed 2025-11-10 | $69.44M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $19.75M 10-Q · filed 2025-08-12 | $35.12M 10-Q · filed 2025-08-12 | $48.81M derived: sum of 3 quarters · filed 2025-08-12 | $58.34M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $15.37M 10-Q · filed 2025-05-13 | $29.06M derived: sum of 2 quarters · filed 2025-05-13 | $38.59M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $13.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $23.22M derived: sum of 2 quarters · filed 2025-03-27 | $39.89M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $9.53M 10-Q · filed 2024-11-12 | $26.20M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |